• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.62%

    Mirati Therapeutics, Inc. (MRTX)

    20.72 Down 0.32(1.52%) Apr 29, 4:00PM EDT
    |After Hours : 20.72 0.00 (0.00%) Apr 29, 4:55PM EDT
    ProfileGet Profile for:
    Mirati Therapeutics, Inc.
    9393 Towne Centre Drive
    Suite 200
    San Diego, CA 92121
    United States - Map
    Phone: 858-332-3410
    Website: http://www.mirati.com

    Index Membership:N/A
    Full Time Employees:33

    Business Summary 

    Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of products targeting oncology. The company’s clinical stage product candidates include MGCD265, a multi-targeted kinase inhibitor that is in Phase 1b clinical development trials for the treatment of patients with non-small cell lung cancer and other solid tumors, such as those found in gastroesophageal cancers, and squamous cell carcinoma of the head and neck; and MGCD516, a kinase inhibitor, which is in Phase Ib clinical development for the treatment of solid tumors with an emphasis on genetic alterations. It also develops Mocetinostat, an orally-bioavailable histone deacetylase inhibitor that is in Phase 2 clinical trial development for patients with bladder cancer, myelodysplastic syndrome, and non-hodgkin's lymphoma, principally diffuse large B-cell lymphoma and follicular lymphoma. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for MGCD265; and a partnership with QIAGEN N.V. to develop and commercialize a companion diagnostic test to guide the use of glesatinib (MGCD265), a targeted therapy under development for non-small cell lung cancer. Mirati Therapeutics, Inc. is headquartered in San Diego, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Mirati Therapeutics, Inc.

    Corporate Governance 
    Mirati Therapeutics, Inc.’s ISS Governance QuickScore as of Apr 1, 2016 is 7. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 3; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Charles M. Baum M.D., Ph.D., 58
    Chief Exec. Officer, Pres and Director
    Mr. Mark J. Gergen J.D., 53
    Chief Operating Officer, Exec. VP and Sec.
    Dr. Isan Chen M.D., 54
    Chief Medical & Devel. Officer and Exec. VP
    Ms. Jamie A. Donadio , 41
    Chief Financial Officer and Sr. VP
    Dr. James Christensen Ph.D., 48
    Chief Scientific Officer and Sr. VP
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders